摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-Isothiocyanatoethyl)-1-methyl-1h-pyrrole | 149488-92-6

中文名称
——
中文别名
——
英文名称
2-(2-Isothiocyanatoethyl)-1-methyl-1h-pyrrole
英文别名
2-(2-isothiocyanatoethyl)-1-methylpyrrole
2-(2-Isothiocyanatoethyl)-1-methyl-1h-pyrrole化学式
CAS
149488-92-6
化学式
C8H10N2S
mdl
——
分子量
166.25
InChiKey
SQVOMSCWFNOXDB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    49.4
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • Novel thiourea derivatives and the pharmaceutical compositions containing the same
    申请人:——
    公开号:US20030153596A1
    公开(公告)日:2003-08-14
    The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.
    本发明涉及一种新型硫脲生物,作为辣椒素受体(VR)的调节剂,以及含有该衍生物的药物组合物。作为与辣椒素受体活性相关的疾病,可以列举急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病变、神经损伤、糖尿病性神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺病等呼吸道疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病。本发明提供了一种用于预防或治疗这些疾病的药物组合物。
  • [EN] NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME<br/>[FR] NOUVEAUX DERIVES DE THIOUREA ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
    申请人:PACIFIC CORP
    公开号:WO2002016318A1
    公开(公告)日:2002-02-28
    The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.
    本发明涉及一种新型硫脲生物,作为vanilloid受体(VR)的调节剂以及含有该化合物的制药组合物。作为与vanilloid受体活性相关的疾病,可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病变、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合症、哮喘或慢性阻塞性肺疾病、皮肤、眼或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了用于预防或治疗这些疾病的制药组合物。
  • EP1303483A4
    申请人:——
    公开号:EP1303483A4
    公开(公告)日:2004-11-03
  • NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
    申请人:PACIFIC CORPORATION
    公开号:EP1303483A1
    公开(公告)日:2003-04-23
  • US8071650B2
    申请人:——
    公开号:US8071650B2
    公开(公告)日:2011-12-06
查看更多